CA2630544A1 - Multiplex digital immuno-sensing using a library of photocleavable mass tags - Google Patents
Multiplex digital immuno-sensing using a library of photocleavable mass tags Download PDFInfo
- Publication number
- CA2630544A1 CA2630544A1 CA002630544A CA2630544A CA2630544A1 CA 2630544 A1 CA2630544 A1 CA 2630544A1 CA 002630544 A CA002630544 A CA 002630544A CA 2630544 A CA2630544 A CA 2630544A CA 2630544 A1 CA2630544 A1 CA 2630544A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- agent
- sample
- mass
- solid substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Abstract
This invention provides methods, compositions and kits for immunosensing using photocleavable mass tags.
Description
MULTIPLEX DIGITAL IMMUNO-SENSING USING A LIBRARY OF
PHOTOCLEAVABLE MASS TAGS
Throughout this application, various publications are referenced in parentheses by name or number. Full citations for these references may be found at the end of each experimental section. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Background Of The Invention Genomics and proteomics are driving forces for new biological discoveries. With the completion of the human genome project (1), researchers are applying this wealth of DNA sequence information to solve unique problems in proteomics. The challenges mostly lie in the characterization of every protein encoded by the human genome, including understanding its structure, function, molecular interactions and regulation in various cell types. The individuality of proteins is indicated by the different types, which number in the thousands, with each protein possessing unique properties. This highlights the need for analytical methods that can satisfy the high throughput and accuracy demanded for this area, especially methods capable of the simultaneous detection of multiple analytes.
A variety of tools have been developed to meet these challenges, employing a diverse range of disciplines ranging from biochemistry, chemistry, physics and material science to microelectronics (2). Among them, the technologies based on the antibody-antigen interaction have emerged to be promising to meet the requirements of these assays because of the specificity and sensitivity of the interaction.
Antibodies are proteins produced by an organism's immune system in response to the presence of foreign substances, antigens. Antibodies have specific affinity for the antigens that elicited their synthesis. The ability of an antibody to interact with its respective antigen has long been a target for manipulation using the immune system of various organisms because it is possible to obtain antibodies that' are specific to a desired target molecule, which forms the basis of immuno-sensing technologies that are specific, sensitive and reproducible.
Most of the immuno-sensing methods available presently are based on the microarray assay format (3). The first immunoassay principles (4) were reported almost 60 years .20 after the characterization of the antibody-antigen interaction in 1900 (5). The discovery of the methods to produce monoclonal antibodies (6) of almost any desired specificity made it possible to develop the immunoassay with higher specificity and affinity. In a solid-phase immunoassay, an antibody specific for a protein of interest is attached to a solid support such as a sheet of polyvinylchloride. The remaining surface is then blocked before the test'sample is applied. A drop of cell extract or a sample of serum or urine is laid on the sheet, which is washed after formation of antibody-antigen complex. Antibody specific for a different site on the antigen is then,added. This secondary antibody carries a radioactive or fluorescent label so that it can be detected. The amount of the secondary antibody bound to the surface is proportional to the quantity of antigen in the sample. The sensitivity of the assay can be further enhanced if the secondary antibody is attached to an enzyme that can convert many molecules of an added colorless substrate into colored products, or nonfluorescent substrates into intensely fluorescent products. This enzyme-linked immunosorbant assay (ELISA), has been used to detect less than 10-9 g c:jf a protein.
Although array-based approaches have become popular tools for biochemistry and molecular biology, limitations still remain which make them incapable of routine use for diagnostic and medical purposes. The preparation of arrays with a diverse set of protein families is still difficult. For example, fluorescence based detection methods suffer from photobleaching, and the limited availability of fluorescent dyes with distinguishable emission wavelength also makes it difficult for multiplex detection. Radioactivity based detection is undesirable for safety reasons. The methods utilizing MALDI-TOF mass spectrometry (7) and surface-plasmon resonance (SPR) spectroscopy (8) are now under rapid development, but no satisfactory success has yet been demonstrated.
PHOTOCLEAVABLE MASS TAGS
Throughout this application, various publications are referenced in parentheses by name or number. Full citations for these references may be found at the end of each experimental section. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Background Of The Invention Genomics and proteomics are driving forces for new biological discoveries. With the completion of the human genome project (1), researchers are applying this wealth of DNA sequence information to solve unique problems in proteomics. The challenges mostly lie in the characterization of every protein encoded by the human genome, including understanding its structure, function, molecular interactions and regulation in various cell types. The individuality of proteins is indicated by the different types, which number in the thousands, with each protein possessing unique properties. This highlights the need for analytical methods that can satisfy the high throughput and accuracy demanded for this area, especially methods capable of the simultaneous detection of multiple analytes.
A variety of tools have been developed to meet these challenges, employing a diverse range of disciplines ranging from biochemistry, chemistry, physics and material science to microelectronics (2). Among them, the technologies based on the antibody-antigen interaction have emerged to be promising to meet the requirements of these assays because of the specificity and sensitivity of the interaction.
Antibodies are proteins produced by an organism's immune system in response to the presence of foreign substances, antigens. Antibodies have specific affinity for the antigens that elicited their synthesis. The ability of an antibody to interact with its respective antigen has long been a target for manipulation using the immune system of various organisms because it is possible to obtain antibodies that' are specific to a desired target molecule, which forms the basis of immuno-sensing technologies that are specific, sensitive and reproducible.
Most of the immuno-sensing methods available presently are based on the microarray assay format (3). The first immunoassay principles (4) were reported almost 60 years .20 after the characterization of the antibody-antigen interaction in 1900 (5). The discovery of the methods to produce monoclonal antibodies (6) of almost any desired specificity made it possible to develop the immunoassay with higher specificity and affinity. In a solid-phase immunoassay, an antibody specific for a protein of interest is attached to a solid support such as a sheet of polyvinylchloride. The remaining surface is then blocked before the test'sample is applied. A drop of cell extract or a sample of serum or urine is laid on the sheet, which is washed after formation of antibody-antigen complex. Antibody specific for a different site on the antigen is then,added. This secondary antibody carries a radioactive or fluorescent label so that it can be detected. The amount of the secondary antibody bound to the surface is proportional to the quantity of antigen in the sample. The sensitivity of the assay can be further enhanced if the secondary antibody is attached to an enzyme that can convert many molecules of an added colorless substrate into colored products, or nonfluorescent substrates into intensely fluorescent products. This enzyme-linked immunosorbant assay (ELISA), has been used to detect less than 10-9 g c:jf a protein.
Although array-based approaches have become popular tools for biochemistry and molecular biology, limitations still remain which make them incapable of routine use for diagnostic and medical purposes. The preparation of arrays with a diverse set of protein families is still difficult. For example, fluorescence based detection methods suffer from photobleaching, and the limited availability of fluorescent dyes with distinguishable emission wavelength also makes it difficult for multiplex detection. Radioactivity based detection is undesirable for safety reasons. The methods utilizing MALDI-TOF mass spectrometry (7) and surface-plasmon resonance (SPR) spectroscopy (8) are now under rapid development, but no satisfactory success has yet been demonstrated.
Summary Of The Invention This invention provides a method for detecting the presence of an agent in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a first antibody which binds to the agent, wherein the contacting is performed under conditions which would permit the first antibody to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a second antibody which binds to the agent concurrently with the first antibody, wherein the second antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the second antibody to bind to the agent if present in the sample;
(d) removing any unbound second antibody;
(e) cleaving the mass tag from any bound second antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention also provides a second method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a plurality of first antibodies, wherein (i) for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent, and (ii) the contacting is performed under conditions which would permit 5 each first antibody to bind to its respective agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of second antibodies, wherein (i) each second antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would pe-rmit each second antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody or antibodies, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent;
(d) removing any unbound second antibodies;
(e) cleaving the mass tags from any bound second antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from a second antibody that binds to the agent indicates that the agent is present in the sample.
This invention further provides a third method for detecting the presence of an agent in a sample comprising:
(a) contacting the sample with a solid substrate which binds to the agent, wherein the contacting is performed under conditions which would permit the solid substrate to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with an antibody which binds to the agent concurrently with the solid substrate, wherein the antibody has a mass tag cleavably affixed thereto, and wherein the contacting is perf-ormed under conditions which would permit the antibody to bind to the agent if present in the sample;
(d) removing any unbound antibody;
(e) cleaving the mass tag from any bound antibody;
and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention further provides a fourth method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate which binds to each agent whose presence in the sample is being detected, wherein the contacting is performed under conditions which would permit the solid substrate to bind to each agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of antibodies, wherein (i) each antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the, contacting is performed under conditions which would permit each antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent concurrently with the solid substrate, and the mass tag or mass tags bound to the antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any antibody which binds to any other agent;
(d) removing any unbound antibodies;
(e) cleaving the mass tags from any bound antibodies; and (f) detecting the presence and determining the mass of any cleaved masstag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from an antibody that binds to the agent indicates that the agent is present in the sample.
This invention also provides a composition of matter comprising:
(a) a solid substrate;
(b) a first antibody bound to the solid substrate, wherein the first antibody recognizes an agent;
(a) contacting the sample with a solid substrate having affixed thereto a first antibody which binds to the agent, wherein the contacting is performed under conditions which would permit the first antibody to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a second antibody which binds to the agent concurrently with the first antibody, wherein the second antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the second antibody to bind to the agent if present in the sample;
(d) removing any unbound second antibody;
(e) cleaving the mass tag from any bound second antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention also provides a second method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a plurality of first antibodies, wherein (i) for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent, and (ii) the contacting is performed under conditions which would permit 5 each first antibody to bind to its respective agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of second antibodies, wherein (i) each second antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would pe-rmit each second antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody or antibodies, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent;
(d) removing any unbound second antibodies;
(e) cleaving the mass tags from any bound second antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from a second antibody that binds to the agent indicates that the agent is present in the sample.
This invention further provides a third method for detecting the presence of an agent in a sample comprising:
(a) contacting the sample with a solid substrate which binds to the agent, wherein the contacting is performed under conditions which would permit the solid substrate to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with an antibody which binds to the agent concurrently with the solid substrate, wherein the antibody has a mass tag cleavably affixed thereto, and wherein the contacting is perf-ormed under conditions which would permit the antibody to bind to the agent if present in the sample;
(d) removing any unbound antibody;
(e) cleaving the mass tag from any bound antibody;
and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention further provides a fourth method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate which binds to each agent whose presence in the sample is being detected, wherein the contacting is performed under conditions which would permit the solid substrate to bind to each agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of antibodies, wherein (i) each antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the, contacting is performed under conditions which would permit each antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent concurrently with the solid substrate, and the mass tag or mass tags bound to the antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any antibody which binds to any other agent;
(d) removing any unbound antibodies;
(e) cleaving the mass tags from any bound antibodies; and (f) detecting the presence and determining the mass of any cleaved masstag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from an antibody that binds to the agent indicates that the agent is present in the sample.
This invention also provides a composition of matter comprising:
(a) a solid substrate;
(b) a first antibody bound to the solid substrate, wherein the first antibody recognizes an agent;
(c) the agent recognized by the first antibody, wherein the agent is bound to the first antibody; and (d) a second antibody which recognizes the agent bound concurrently to the first antibody, wherein the second antibody is bound to the agent, and wherein the second antibody has a mass tag cleavably affixed thereto This invention further provides a first kit for detecting the presence of an agent in a sample comprising:
(a) a solid substrate;
(b) a first antibody for affixing to the solid substrate, which first antibody recognizes"the i5 agent;
(c)' a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (d) instructions for using the kit to detect the presence of the agent in the sample.
This invention further provides a second kit for detecting the presence of an agent in a sample comprising:
(a) a solid substrate having affixed thereto a first antibody which recognizes the agent;
(b) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (c) instructions for using the kit to detect the presence of the agent in the sample.
(a) a solid substrate;
(b) a first antibody for affixing to the solid substrate, which first antibody recognizes"the i5 agent;
(c)' a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (d) instructions for using the kit to detect the presence of the agent in the sample.
This invention further provides a second kit for detecting the presence of an agent in a sample comprising:
(a) a solid substrate having affixed thereto a first antibody which recognizes the agent;
(b) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (c) instructions for using the kit to detect the presence of the agent in the sample.
This invention further provides a third kit for detecting the presence of an agent in a sample comprising:
(a) a solid substrate which binds the agent;
(b) an antibody having a mass tag cleavably affixed thereto, which antibody recognizes the agent;
and (c) instructions for using the kit to detect the presence of the agent in the sample.
This invention further provides a fourth kit for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) a solid substrate;
(b) a plurality of first antibodies for affixing to the solid substrate wherein for each agent whose presence is being detected in the sample there is at least one first antibody which binds to the agent;
(c) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (d) instructions for using the kit to detect the presence in the sample of one or more agents.
This invention further provides a fifth kit for detecting the presence in a sample of one or more of a plurality of agents comprising:
(a) a solid substrate having a plurality of first 5 antibodies affixed thereto wherein for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent;
(b) a plurality of second antibodies each having a 10 mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is1to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass Lag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
Finally, this invention provides a sixth kit for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) a solid substrate which binds each of the agents whose presence is to be detected;
(b) a plurality of antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is being detected, there is at,least one antibody which binds to the agent; and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
(a) a solid substrate which binds the agent;
(b) an antibody having a mass tag cleavably affixed thereto, which antibody recognizes the agent;
and (c) instructions for using the kit to detect the presence of the agent in the sample.
This invention further provides a fourth kit for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) a solid substrate;
(b) a plurality of first antibodies for affixing to the solid substrate wherein for each agent whose presence is being detected in the sample there is at least one first antibody which binds to the agent;
(c) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (d) instructions for using the kit to detect the presence in the sample of one or more agents.
This invention further provides a fifth kit for detecting the presence in a sample of one or more of a plurality of agents comprising:
(a) a solid substrate having a plurality of first 5 antibodies affixed thereto wherein for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent;
(b) a plurality of second antibodies each having a 10 mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is1to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass Lag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
Finally, this invention provides a sixth kit for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) a solid substrate which binds each of the agents whose presence is to be detected;
(b) a plurality of antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is being detected, there is at,least one antibody which binds to the agent; and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
Brief Description of the Figures Figure 1. Schematic of simultaneous immunosensing of different antigens using photocleaveable mass tag-labeled antibodies.
Figure 2. Synthesis of four different photocleavable mass tag NHS esters.
Figure 3. Photocleavage of photocleavable mass tag labeled detection antibodies under irradiation with U.V.
Light at about 340nm.
Figure 2. Synthesis of four different photocleavable mass tag NHS esters.
Figure 3. Photocleavage of photocleavable mass tag labeled detection antibodies under irradiation with U.V.
Light at about 340nm.
Detailed Description of the Invention Terms The following terms are presented as an aid in understanding this invention:
APCI - Atmospheric Pressure Chemical Ionization;
PC - Photocleaveable SEB - Staphylococcal Enterotoxin B
W - Ultra Violet "Agent" shall mean an entity, e.g. one present in a biological sample, which is recognized by an antibody.
Agents include, for example, a polypeptide or an antigenic fragment of a polypeptide, a glycomer, a lectin, a nucleic acid, a bacterium, a virus, and any combination thereof.
"Antibody" shall include, without limitation, (a) an immunoglobulin molecule comprising two heavy chains and two light chains and which recognizes an antigen; (b) a polyclonal or monoclonal immunoglobulin molecule; and (c) a monovalent or divalent fragment thereof. Immunoglobulin molecules may derive from any of the commonly known classes, including but not limited to IgA, secretory IgA, IgG, IgE and IgM. IgG subclasses are well known to those in the art and include, but are not limited to, human IgGi, IgG2, IgG3 and IgG4. Antibodies can be both naturally occurring and non-naturally occurring.
Furthermore, antibodies include chimeric antibodies, wholly synthetic antibodies, single chain antibodies, and fragments thereof. Antibodies may be human or nonhuman.
Antibody fragments include, without limitation, Fab fragments, Fv fragments and other antigen-binding fragments.
"Mass tag" shall mean a molecular entity of a predetermined size which is capable of being attached by a cleavable bond to another entity.
"Solid substrate" shall mean any suitable medium present in the solid phase to which an antibody or an agent may be affixed.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Embodiments of the Invention This invention relates to a novel multiplex digital immuno-sensing approach that is based on the detection of photocleavable mass tags by Atmospheric Pressure Chemical Ionization (APCI) mass spectrometry. The mass tags have unique mass values and can be detected with almost real-time response. The whole process can be performed in a small vial for the simultaneous detection of multiple analytes,- facilitating easy and rapid measurement. The success of this approach permits use of immuno-sensing systems for various applications.
Specifically, this invention provides a first method for detecting the presence of an agent in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a first antibody which binds to the agent, wherein the contacting is performed under conditions which would permit the first antibody to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a second antibody which binds to the agent concurrently with the first antibody, wherein the second antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the second antibody to bind to the agent if present in the sample;
(d) removing any unbound second antibody;
(e) cleaving the mass tag from any bound second antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention also provides a second method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a plurality of first antibodies, wherein (i) for each agent whose presence in the sample is being detected, 5 there is at least one first antibody which binds to the agent, and (ii) the contacting is performed under conditions which would permit each first antibody to bind to its respective agent if present in the sample;
10 (b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of second antibodies, wherein (i) each second antibody has a mass tag of 15 predetermined mass cleavably affixed thereto,',~(ii) the contacting is performed under conditions which would permit each second antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody or antibodies, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent;
(d) removing any unbound second antibodies;
(e) cleaving the mass tags from any bound second antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from a second antibody that binds to the agent indicates that the agent is present in the sample.
This invention also provides a third method for detecting the presence of an agent in a sample comprising:
(a) contacting the sartiple with a solid substrate which binds to the agent, wherein the contacting is performed under conditions which would permit the solid substrate to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with an antibody which binds to the agent concurrently with the solid substrate, wherein the antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the antibody to bind to the agent if present in the sample;
(d) removing any unbound antibody;
(e) cleaving the mass tag from any bound antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention also provides a fourth method for detecting the presence of one or more of a plurality of agents in a sample comprising:
APCI - Atmospheric Pressure Chemical Ionization;
PC - Photocleaveable SEB - Staphylococcal Enterotoxin B
W - Ultra Violet "Agent" shall mean an entity, e.g. one present in a biological sample, which is recognized by an antibody.
Agents include, for example, a polypeptide or an antigenic fragment of a polypeptide, a glycomer, a lectin, a nucleic acid, a bacterium, a virus, and any combination thereof.
"Antibody" shall include, without limitation, (a) an immunoglobulin molecule comprising two heavy chains and two light chains and which recognizes an antigen; (b) a polyclonal or monoclonal immunoglobulin molecule; and (c) a monovalent or divalent fragment thereof. Immunoglobulin molecules may derive from any of the commonly known classes, including but not limited to IgA, secretory IgA, IgG, IgE and IgM. IgG subclasses are well known to those in the art and include, but are not limited to, human IgGi, IgG2, IgG3 and IgG4. Antibodies can be both naturally occurring and non-naturally occurring.
Furthermore, antibodies include chimeric antibodies, wholly synthetic antibodies, single chain antibodies, and fragments thereof. Antibodies may be human or nonhuman.
Antibody fragments include, without limitation, Fab fragments, Fv fragments and other antigen-binding fragments.
"Mass tag" shall mean a molecular entity of a predetermined size which is capable of being attached by a cleavable bond to another entity.
"Solid substrate" shall mean any suitable medium present in the solid phase to which an antibody or an agent may be affixed.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Embodiments of the Invention This invention relates to a novel multiplex digital immuno-sensing approach that is based on the detection of photocleavable mass tags by Atmospheric Pressure Chemical Ionization (APCI) mass spectrometry. The mass tags have unique mass values and can be detected with almost real-time response. The whole process can be performed in a small vial for the simultaneous detection of multiple analytes,- facilitating easy and rapid measurement. The success of this approach permits use of immuno-sensing systems for various applications.
Specifically, this invention provides a first method for detecting the presence of an agent in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a first antibody which binds to the agent, wherein the contacting is performed under conditions which would permit the first antibody to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a second antibody which binds to the agent concurrently with the first antibody, wherein the second antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the second antibody to bind to the agent if present in the sample;
(d) removing any unbound second antibody;
(e) cleaving the mass tag from any bound second antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention also provides a second method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a plurality of first antibodies, wherein (i) for each agent whose presence in the sample is being detected, 5 there is at least one first antibody which binds to the agent, and (ii) the contacting is performed under conditions which would permit each first antibody to bind to its respective agent if present in the sample;
10 (b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of second antibodies, wherein (i) each second antibody has a mass tag of 15 predetermined mass cleavably affixed thereto,',~(ii) the contacting is performed under conditions which would permit each second antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody or antibodies, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent;
(d) removing any unbound second antibodies;
(e) cleaving the mass tags from any bound second antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from a second antibody that binds to the agent indicates that the agent is present in the sample.
This invention also provides a third method for detecting the presence of an agent in a sample comprising:
(a) contacting the sartiple with a solid substrate which binds to the agent, wherein the contacting is performed under conditions which would permit the solid substrate to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with an antibody which binds to the agent concurrently with the solid substrate, wherein the antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the antibody to bind to the agent if present in the sample;
(d) removing any unbound antibody;
(e) cleaving the mass tag from any bound antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
This invention also provides a fourth method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate which binds to each agent whose presence in the sample is being detected, wherein the contacting is performed under conditions which would permit the solid substrate to bind to each agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of antibodies, wherein (i) each antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would permit each antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent concurrently with the solid substrate, and the mass tag or mass tags bound to the antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any antibody which binds to any other agent;
(d) removing any unbound antibodies;
(e) cleaving the mass tags from any bound antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from an antibody that binds to the agent indicates that the agent is present in the sample.
In one embodiment of each of the instant methods, the sample is an aqueous cell suspension, a cell lysate, blood, plasma, lymph, cerebro-spinal fluid, tears, saliva, urine, synovial fluid, or a fluid derived from any of the above. In another embodiment, the sample is of mammalian origin, preferably of human origin. In another embodiment, the sample is of avian origin.
In one embodiment of each of the instant methods, each antibody is a monoclonal antibody, e.g., a chimeric monoclonal antibody.
In another embodiment of the instant methods, the cleavable mass tag can be cleaved chemically, by ultraviolet light, by heat, or by laser. In another embodiment, the cleaved mass tag is detected by mass spectrometry. The mass spectrometry can be, for example, atmospheric pressure chemical ionization mass spectrometry, electrospray ionization mass spectrometry, or matrix assisted laser desorption ionization mass spectrometry.
In a further embodiment of the instant methods, the solid substrate is glass, quartz, silicon, plastic, or gold, and can be for example, in the form of a bead, a chip, or a well. In this invention, each antibody affixed to a solid substrate can be affixed, for example, via a streptavidin-biotin link or via 1,3-dipolar cycloaddition. In the instant methods, the agent detected can be, for example, a bacterial antigen or a viral antigen. In one embodiment of the instant methods, each mass tag has a molecular weight of from about 100Da to about 2,500Da. In one embodiment, one mass tag has the structure:
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of antibodies, wherein (i) each antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would permit each antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent concurrently with the solid substrate, and the mass tag or mass tags bound to the antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any antibody which binds to any other agent;
(d) removing any unbound antibodies;
(e) cleaving the mass tags from any bound antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from an antibody that binds to the agent indicates that the agent is present in the sample.
In one embodiment of each of the instant methods, the sample is an aqueous cell suspension, a cell lysate, blood, plasma, lymph, cerebro-spinal fluid, tears, saliva, urine, synovial fluid, or a fluid derived from any of the above. In another embodiment, the sample is of mammalian origin, preferably of human origin. In another embodiment, the sample is of avian origin.
In one embodiment of each of the instant methods, each antibody is a monoclonal antibody, e.g., a chimeric monoclonal antibody.
In another embodiment of the instant methods, the cleavable mass tag can be cleaved chemically, by ultraviolet light, by heat, or by laser. In another embodiment, the cleaved mass tag is detected by mass spectrometry. The mass spectrometry can be, for example, atmospheric pressure chemical ionization mass spectrometry, electrospray ionization mass spectrometry, or matrix assisted laser desorption ionization mass spectrometry.
In a further embodiment of the instant methods, the solid substrate is glass, quartz, silicon, plastic, or gold, and can be for example, in the form of a bead, a chip, or a well. In this invention, each antibody affixed to a solid substrate can be affixed, for example, via a streptavidin-biotin link or via 1,3-dipolar cycloaddition. In the instant methods, the agent detected can be, for example, a bacterial antigen or a viral antigen. In one embodiment of the instant methods, each mass tag has a molecular weight of from about 100Da to about 2,500Da. In one embodiment, one mass tag has the structure:
O
O
I{
O-C-O-N
x wherein X is H, F,- OMe, or (OMe)2.
This invention also provides a composition of matter comprising: (a) a solid substrate; (b) a first antibody bound to the solid substrate, wherein the first antibody recognizes an agent; (c) the agent recognized by the first antibody, wherein the agent is bound to the first antibody; and (d) a second antibody which recognizes the agent bound concurrently to the first antibody, wherein the second antibody is bound to the agent, and wherein the second antibody has a mass tag cleavably affixed thereto.
This invention further provides a first kit for detecting the presence of an agent in a sample comprising: (a) a solid substrate; (b) a first antibody for affixing to the solid substrate, which first antibody recognizes the agent; (c) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (d) instructions for using the kit to detect the presence of the agent in the sample.
This invention also provides a second kit for detecting the presence of an agent in a sample comprising: (a) a solid substrate having affixed thereto a first antibody which recognizes the agent; (b) a second antibody having a mass tag cleavably affixed thereto, which second 5 antibody recognizes the agent concurrently with the first antibody; and (c) instructions for using the kit to detect the presence of the agent in the sample.
This invention also provides a third kit for detecting 10 the presence of an agent in a sample comprising: (a) a solid substrate which binds the agent; (b) an antibody having a mass tag cleavably affixed thereto, which antibody recognizes the agent; and (c) instructions for using the kit to detect the presence of the agent in the 15 sample.
This invention also provides a fourth kit for detecting the presence of one or more of a plurality of agents in a sample comprising: (a) a solid substrate; (b) a plurality 20 of first antibodies for affixing to the solid substrate wherein for each agent whose presence is being detected in the sample there is at least one first antibody which binds to the agent; (c) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein f or each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (d) instructions for using the kit to detect the presence in the sample of one or more agents.
O
I{
O-C-O-N
x wherein X is H, F,- OMe, or (OMe)2.
This invention also provides a composition of matter comprising: (a) a solid substrate; (b) a first antibody bound to the solid substrate, wherein the first antibody recognizes an agent; (c) the agent recognized by the first antibody, wherein the agent is bound to the first antibody; and (d) a second antibody which recognizes the agent bound concurrently to the first antibody, wherein the second antibody is bound to the agent, and wherein the second antibody has a mass tag cleavably affixed thereto.
This invention further provides a first kit for detecting the presence of an agent in a sample comprising: (a) a solid substrate; (b) a first antibody for affixing to the solid substrate, which first antibody recognizes the agent; (c) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (d) instructions for using the kit to detect the presence of the agent in the sample.
This invention also provides a second kit for detecting the presence of an agent in a sample comprising: (a) a solid substrate having affixed thereto a first antibody which recognizes the agent; (b) a second antibody having a mass tag cleavably affixed thereto, which second 5 antibody recognizes the agent concurrently with the first antibody; and (c) instructions for using the kit to detect the presence of the agent in the sample.
This invention also provides a third kit for detecting 10 the presence of an agent in a sample comprising: (a) a solid substrate which binds the agent; (b) an antibody having a mass tag cleavably affixed thereto, which antibody recognizes the agent; and (c) instructions for using the kit to detect the presence of the agent in the 15 sample.
This invention also provides a fourth kit for detecting the presence of one or more of a plurality of agents in a sample comprising: (a) a solid substrate; (b) a plurality 20 of first antibodies for affixing to the solid substrate wherein for each agent whose presence is being detected in the sample there is at least one first antibody which binds to the agent; (c) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein f or each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (d) instructions for using the kit to detect the presence in the sample of one or more agents.
This invention also provides a fifth kit for detecting the presence in a sample of one or more of a plurality of agents comprising: (a) a solid substrate having a plurality of first antibodies affixed thereto wherein for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent; (b) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
Finally, this invention provides a sixth kit for detecting the presence of one or more of a plurality of agents in a sample comprising: (a) a solid substrate which binds each of the agents whose presence is to be detected; (b) a plurality of antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent;
and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
In one embodiment of each of the instant kits, the sample is an aqueous cell suspension, a cell lysate, blood, plasma, lymph, cerebro-spinal fluid, tears, saliva, urine, synovial fluid, or a fluid derived from any of the above. In another embodiment, the sample is of mammalian origin, preferably of human origin. In another embodiment, the sample is of avian origin.
In one embodiment of each of the instant kits, each antibody is a monoclonal antibody, e.g., a chimeric monoclonal antibody.
In another embodiment of the instant kits, the cleavable mass tag is cleaved chemically, by ultraviolet light, by heat, or by laser. In another embodiment, the cleaved mass tag is detected by mass spectrometry. The mass spectrometry can be, for example atmospheric pressure chemical ionization mass spectrometry, electrospray ionization mass spectrometry, or matrix assisted laser desorption ionization mass spectrometry.
In a further embodiment of the instant kits, the solid substrate is glass, quartz, silicon, plastic, or gold, and can be for example, in the form of a bead, a chip, or a well. In this invention, each antibody affixed to a solid substrate can be affixed, for example, via a streptavidin-biotin link or via 1,3-dipolar cycloaddition. In the instant kits, the agent detected can be, for example, a bacterial antigen or a viral antigen. In one embodiment of the instant kits, each mass tag has a molecular weight of from about 100Da to about 2,500Da. In one embodiment, one mass tag has the structure:
Finally, this invention provides a sixth kit for detecting the presence of one or more of a plurality of agents in a sample comprising: (a) a solid substrate which binds each of the agents whose presence is to be detected; (b) a plurality of antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent;
and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
In one embodiment of each of the instant kits, the sample is an aqueous cell suspension, a cell lysate, blood, plasma, lymph, cerebro-spinal fluid, tears, saliva, urine, synovial fluid, or a fluid derived from any of the above. In another embodiment, the sample is of mammalian origin, preferably of human origin. In another embodiment, the sample is of avian origin.
In one embodiment of each of the instant kits, each antibody is a monoclonal antibody, e.g., a chimeric monoclonal antibody.
In another embodiment of the instant kits, the cleavable mass tag is cleaved chemically, by ultraviolet light, by heat, or by laser. In another embodiment, the cleaved mass tag is detected by mass spectrometry. The mass spectrometry can be, for example atmospheric pressure chemical ionization mass spectrometry, electrospray ionization mass spectrometry, or matrix assisted laser desorption ionization mass spectrometry.
In a further embodiment of the instant kits, the solid substrate is glass, quartz, silicon, plastic, or gold, and can be for example, in the form of a bead, a chip, or a well. In this invention, each antibody affixed to a solid substrate can be affixed, for example, via a streptavidin-biotin link or via 1,3-dipolar cycloaddition. In the instant kits, the agent detected can be, for example, a bacterial antigen or a viral antigen. In one embodiment of the instant kits, each mass tag has a molecular weight of from about 100Da to about 2,500Da. In one embodiment, one mass tag has the structure:
O
6:LoN
X
wherein X is H, F, OMe, or (OMe) 2.
This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.
6:LoN
X
wherein X is H, F, OMe, or (OMe) 2.
This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.
Experimental Details Here we disclose the design and synthesis of a library of photocleavable mass tags that can be conjugated to a variety of antibodies. The mass tags are designed so that they can'be cleaved by irradiation with near-UV light (-340nm) after conjugation with antibodies, and the photocleavage products can be detected by Atmospheric Pressure Chemical Ionization (APCI) mass spectrometry. In addition, screening the binding reactivity of photocleavable mass tag-labeled antibodies for their corresponding antigens is disclosed here, as well as the use of the photocleavable mass tag-labeled antibodies, biotin-labeled antibodies, streptavidin-coated solid surfaces and a mass spectrometer in a system that is capable of multiplex digital immuno-sensing.
In one embodiment of the immuno-sensing method disclosed here, the immobilization of the biotin-labeled antibodies to a streptavidin-coated solid surface and subsequent blocking of the remaining surface before test antigens are applied is employed. The antigens that are captured by the immobilized antibodies can be identified by the addition of a second set of photocleavable mass tag-labeled antibodies that recognize a different epitope of the antigens. The identity of the captured antigens can be revealed by the unique mass values associated with mass tags generated by UV irradiation on the solid surface. In one embodiment, the whole process is perfoxmed in one tube, allowing rapid detection for multiple analytes.
Design of a multiplex immuno-sensing method using photocleavable mass tags One embodiment of the immuno-sensing method using 5 photocleavable mass tags is shown in Figure 1. The system consists of a solid support (such as beads with large surface area) with immobilized antibodies as capture antibodies that are able to bind to their specific target antigens in complex biological solutions, such as a cell 10 extract. Upon adding the sample solution containing various antigens, only the antigens that can interact with the immobilized antibodies will be bound to the solid surface. After removing excess reagents and washing away any unbound proteins on the solid surface, the 15 photocleavable mass tag-labeled detection antibodies are added, each of which can interact with a different epitope on the antigens. After washing away the excess reagents from the solid surface, UV irradiation is applied to cleave the photocleavable mass tags from the 20 antibody-antigen complex on the surface. The mass tags that are released into the solution are identified by an APCI mass spectrometer. For initial experiments, four kinds of antigens and their corresponding antibodies are used to validate the whole process. Streptavidin-coated 25 magnetic beads are used as the solid surface to bind the biotinylated capture antibodies. The entire process is performed in a small vial and capillary tubing is used to transfer the solution into an APCI mass spectrometer for detection.
In one embodiment of the immuno-sensing method disclosed here, the immobilization of the biotin-labeled antibodies to a streptavidin-coated solid surface and subsequent blocking of the remaining surface before test antigens are applied is employed. The antigens that are captured by the immobilized antibodies can be identified by the addition of a second set of photocleavable mass tag-labeled antibodies that recognize a different epitope of the antigens. The identity of the captured antigens can be revealed by the unique mass values associated with mass tags generated by UV irradiation on the solid surface. In one embodiment, the whole process is perfoxmed in one tube, allowing rapid detection for multiple analytes.
Design of a multiplex immuno-sensing method using photocleavable mass tags One embodiment of the immuno-sensing method using 5 photocleavable mass tags is shown in Figure 1. The system consists of a solid support (such as beads with large surface area) with immobilized antibodies as capture antibodies that are able to bind to their specific target antigens in complex biological solutions, such as a cell 10 extract. Upon adding the sample solution containing various antigens, only the antigens that can interact with the immobilized antibodies will be bound to the solid surface. After removing excess reagents and washing away any unbound proteins on the solid surface, the 15 photocleavable mass tag-labeled detection antibodies are added, each of which can interact with a different epitope on the antigens. After washing away the excess reagents from the solid surface, UV irradiation is applied to cleave the photocleavable mass tags from the 20 antibody-antigen complex on the surface. The mass tags that are released into the solution are identified by an APCI mass spectrometer. For initial experiments, four kinds of antigens and their corresponding antibodies are used to validate the whole process. Streptavidin-coated 25 magnetic beads are used as the solid surface to bind the biotinylated capture antibodies. The entire process is performed in a small vial and capillary tubing is used to transfer the solution into an APCI mass spectrometer for detection.
Synthesis of biotinylated antibodies as capture antibodies Four target antigens and corresponding antibodies are used for initial experiments: staphylococcal enterotoxin B (SEB) and rabbit anti-SEB IgG (Toxin Technology, Sarasota, FL), plague Fl antigen and monoclonal antibody YPF-6H3-1-1-IgG (6H3) (9), D-dimer and nionocldnal DD-3B6/22 (capture) and DD-4D2/182 (detection) (Agen Biomedical Ltd, Brisbane, Australia), Chicken IgY and rabbit anti-chicken antibody (Jackson Immuno-Research, West Grove, CA). All the samples used here are of diagnostic importance and the need for rapid detection has been validated. Biotin is introduced onto the hinge sulfhydryl group of DD-3B6/22 Fab' fragment according to Savage et al. (10) . Anti-SEB IgG, 6H3 and rabbit anti-chicken antibody are labeled with biotin-LC-N-hydroxysuccinimidyl ester (Pierce, Rockford, IL) at pH=9 at a 5:1 ratio (biotin: antibody) (10); unincorporated biotin is removed from labeled proteins by dialysis or gel filtration.
Synthesis of photocleavable mass tag-labeled detection antibodies Four detection antibodies can be synthesized by attaching a unique photocleavable mass tag label to each one. The synthesis of four active photocleavable mass tag NHS
esters is shown in Figure 2. Each of these four mass tag NHS esters can be introduced to each of the four antibodies mentioned above by a similar procedure (10).
The photocleavable 2-nitrobenzyl moiety has previously been used for a variety of applications (11) and can be efficiently cleaved by W irradiation with a wavelength above 320 nm under which the proteins will not be damaged. The photocleavage reaction of the mass tag-labeled detection antibodies is shown in Figure 3. The unique mass value of the photocleavage product 2-nitroso derivative serves as a unique mass tag for each of the four detection antibodies.
Immuno-sensing using the mass tag-=labeled detection antibodies Streptavidin-coated magnetic beads (Seradyn, Indianapolis) can be used as the solid surface to bind the biotinylated capture antibodies. Ideally, the binding of each of the four biotinylated capture antibodie's is done separately and bovine serum albumin (BSA) can be used to block the remaining surface to prevent unspecific binding. A portion of each solution is mixed in a small test tube to assure that all the four biotinylated capture antibodies are evenly distributed in solution.
After the sample solution that contains one or several antigens is added to the test tube and incubated for binding, the excess reagents are washed away and then the photocleavable mass tag-labeled detection antibodies are introduced into the system. The solid phase beads are then rinsed again to remove all the unbound detection antibodies. W irradiation can then be applied to cleave the tags. The solution containing the cleaved mass tags is transferred into the APCI mass spectrometer for measurement to give the identity of the bound antibodies and therefore the identity of the bound antigens. Figure 3 shows photocleavage of photocleavable mass tag-labeled detection antibodies under irradiation of with UV light (- 340 nm).
Synthesis of photocleavable mass tag-labeled detection antibodies Four detection antibodies can be synthesized by attaching a unique photocleavable mass tag label to each one. The synthesis of four active photocleavable mass tag NHS
esters is shown in Figure 2. Each of these four mass tag NHS esters can be introduced to each of the four antibodies mentioned above by a similar procedure (10).
The photocleavable 2-nitrobenzyl moiety has previously been used for a variety of applications (11) and can be efficiently cleaved by W irradiation with a wavelength above 320 nm under which the proteins will not be damaged. The photocleavage reaction of the mass tag-labeled detection antibodies is shown in Figure 3. The unique mass value of the photocleavage product 2-nitroso derivative serves as a unique mass tag for each of the four detection antibodies.
Immuno-sensing using the mass tag-=labeled detection antibodies Streptavidin-coated magnetic beads (Seradyn, Indianapolis) can be used as the solid surface to bind the biotinylated capture antibodies. Ideally, the binding of each of the four biotinylated capture antibodie's is done separately and bovine serum albumin (BSA) can be used to block the remaining surface to prevent unspecific binding. A portion of each solution is mixed in a small test tube to assure that all the four biotinylated capture antibodies are evenly distributed in solution.
After the sample solution that contains one or several antigens is added to the test tube and incubated for binding, the excess reagents are washed away and then the photocleavable mass tag-labeled detection antibodies are introduced into the system. The solid phase beads are then rinsed again to remove all the unbound detection antibodies. W irradiation can then be applied to cleave the tags. The solution containing the cleaved mass tags is transferred into the APCI mass spectrometer for measurement to give the identity of the bound antibodies and therefore the identity of the bound antigens. Figure 3 shows photocleavage of photocleavable mass tag-labeled detection antibodies under irradiation of with UV light (- 340 nm).
Multiple photocleavable mass tag-labeled detection antibodies, with a unique mass tag for each of the antibodies being assayed, permits high multiplexing immunoassays.
References 1. Science, (2003) issue of April 11; Nature, (2003) issue of April 24.
2. Phizicky, E., Bastiaens, P. I. H., Zhu, H., Snyder, M. & Fields, S. Nature (2003) 422,208-215.
3. Kodadek, T. Chem. Biol. (2001) 8, 105-115.
4. Ya low, R.S. & Berson, S.A. Nature (1959) 184, 1648-1649.
5. Ehrlich, P. Proc. R. Soc. London, (1900) 66, 424.
6. Kohler, G. & Milstein, C.A, Nature, (1975) 256, 495-497.
7. Gygi, S.P., Rist, B., Gerber, S.A., Turecek, F., Gelb, M.H. & Aebersold, R. Nat. Biotechnol. (1999) 17, 949-999.
8. Cooper, M.A. Nat. Rev. Drug. Discov. (2002) 1, 515-528.
9. Cao, L. K., Anderson, G. P., Ligler, F.S. & Ezzell, J. J. Clin. Microbiol. (1995) 33, 336-41.
10. Savage, D., Mattson, G., Desai, S., Nielander, G., Morgensen, S. & Conklin, E. Avidin-Biotin Chemistry: A handbook. (1992) Pierce: Rockford, IL.
11. Guillier, F., Orain, D. & Bradley, M. Chem. Rev.
(2000) 100, 2091-2157.
2. Phizicky, E., Bastiaens, P. I. H., Zhu, H., Snyder, M. & Fields, S. Nature (2003) 422,208-215.
3. Kodadek, T. Chem. Biol. (2001) 8, 105-115.
4. Ya low, R.S. & Berson, S.A. Nature (1959) 184, 1648-1649.
5. Ehrlich, P. Proc. R. Soc. London, (1900) 66, 424.
6. Kohler, G. & Milstein, C.A, Nature, (1975) 256, 495-497.
7. Gygi, S.P., Rist, B., Gerber, S.A., Turecek, F., Gelb, M.H. & Aebersold, R. Nat. Biotechnol. (1999) 17, 949-999.
8. Cooper, M.A. Nat. Rev. Drug. Discov. (2002) 1, 515-528.
9. Cao, L. K., Anderson, G. P., Ligler, F.S. & Ezzell, J. J. Clin. Microbiol. (1995) 33, 336-41.
10. Savage, D., Mattson, G., Desai, S., Nielander, G., Morgensen, S. & Conklin, E. Avidin-Biotin Chemistry: A handbook. (1992) Pierce: Rockford, IL.
11. Guillier, F., Orain, D. & Bradley, M. Chem. Rev.
(2000) 100, 2091-2157.
Claims (40)
1. A method for detecting the presence of an agent in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a first antibody which binds to the agent, wherein the contacting is performed under conditions which would permit the first antibody to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a second antibody which binds to the agent concurrently with the first antibody, wherein the second antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the second antibody to bind to the agent if present in the sample;
(d) removing any unbound second antibody;
(e) cleaving the mass tag from any bound second antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
(a) contacting the sample with a solid substrate having affixed thereto a first antibody which binds to the agent, wherein the contacting is performed under conditions which would permit the first antibody to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a second antibody which binds to the agent concurrently with the first antibody, wherein the second antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the second antibody to bind to the agent if present in the sample;
(d) removing any unbound second antibody;
(e) cleaving the mass tag from any bound second antibody; and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
2. A method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate having affixed thereto a plurality of first antibodies, wherein (i) for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent, and (ii) the contacting is performed under conditions which would permit each first antibody to bind to its respective agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of second antibodies, wherein (i) each second antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would permit each second antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody or antibodies, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent;
(d) removing any unbound second antibodies;
(e) cleaving the mass tags from any bound second antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from a second antibody that binds to the agent indicates that the agent is present in the sample.
(a) contacting the sample with a solid substrate having affixed thereto a plurality of first antibodies, wherein (i) for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent, and (ii) the contacting is performed under conditions which would permit each first antibody to bind to its respective agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of second antibodies, wherein (i) each second antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would permit each second antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody or antibodies, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent;
(d) removing any unbound second antibodies;
(e) cleaving the mass tags from any bound second antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from a second antibody that binds to the agent indicates that the agent is present in the sample.
3. A method for detecting the presence of an agent in a sample comprising:
(a) contacting the sample with a solid substrate which binds to the agent, wherein the contacting is performed under conditions which would permit the solid substrate to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with an antibody which binds to the agent concurrently with the solid substrate, wherein the antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the antibody to bind to the agent if present in the sample;
(d) removing any unbound antibody;
(e) cleaving the mass tag from any bound antibody;
and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
(a) contacting the sample with a solid substrate which binds to the agent, wherein the contacting is performed under conditions which would permit the solid substrate to bind to the agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with an antibody which binds to the agent concurrently with the solid substrate, wherein the antibody has a mass tag cleavably affixed thereto, and wherein the contacting is performed under conditions which would permit the antibody to bind to the agent if present in the sample;
(d) removing any unbound antibody;
(e) cleaving the mass tag from any bound antibody;
and (f) detecting the presence of any cleaved mass tag, wherein the presence of cleaved mass tag indicates that the agent is present in the sample.
4. A method for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) contacting the sample with a solid substrate which binds to each agent whose presence in the sample is being detected, wherein the contacting is performed under conditions which would permit the solid substrate to bind to each agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of antibodies, wherein (i) each antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would permit each antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent concurrently with the solid substrate, and the mass tag or mass tags bound to the antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any antibody which binds to any other agent;
(d) removing any unbound antibodies;
(e) cleaving the mass tags from any bound antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from an antibody that binds to the agent indicates that the agent is present in the sample.
(a) contacting the sample with a solid substrate which binds to each agent whose presence in the sample is being detected, wherein the contacting is performed under conditions which would permit the solid substrate to bind to each agent if present in the sample;
(b) removing any unbound sample from the solid substrate;
(c) contacting the solid substrate with a plurality of antibodies, wherein (i) each antibody has a mass tag of predetermined mass cleavably affixed thereto, (ii) the contacting is performed under conditions which would permit each antibody to bind to its respective agent if present in the sample, and (iii) for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent concurrently with the solid substrate, and the mass tag or mass tags bound to the antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any antibody which binds to any other agent;
(d) removing any unbound antibodies;
(e) cleaving the mass tags from any bound antibodies; and (f) detecting the presence and determining the mass of any cleaved mass tag, whereby, for each agent whose presence in the sample is being detected, the presence of a mass tag cleaved from an antibody that binds to the agent indicates that the agent is present in the sample.
5. The method of claim 1, 2, 13, or 4, wherein the sample is an aqueous cell suspension, a cell lysate, blood, plasma, lymph, cerebro-spinal fluid, tears, saliva, urine, synovial fluid, or a fluid derived from any of the above.
6. The method of claim 1, 2, 3, or 4, wherein the sample is of mammalian origin.
7. The method of claim 6, wherein the sample is of human origin.
8. The method of claim 1, 2, 3, or 4, wherein the sample is of avian origin.
9. The method of claim 1, 2, 3, or 4, wherein each antibody is a monoclonal antibody.
10. The method of claim 9, wherein the monoclonal antibody is a chimeric monoclonal antibody.
11. The method of claim 1, 2, 3, or 4, wherein the cleavable mass tag is cleaved chemically, by ultraviolet light, by heat, or by laser.
12. The method of claim 1, 2, 3, or 4, wherein the cleaved mass tag is detected by mass spectrometry.
13. The method of claim 12, wherein the mass spectrometry is atmospheric pressure chemical ionization mass spectrometry, electrospray ionization mass spectrometry, or matrix assisted laser desorption ionization mass spectrometry.
14. The method of claim 1, 2, 3, or 4, wherein the solid substrate is glass, quartz, silicon, plastic, or gold.
15. The method of claim 14, wherein the solid substrate is a bead, a chip, or a well.
16. The method of claim 1 or 2, wherein each first antibody is affixed to the solid substrate via a streptavidin-biotin link or via 1,3-dipolar cycloaddition.
17. The method of claim 1, 2, 3, or 4, wherein the agent is a bacterial antigen or a viral antigen.
18. The method of claim 1, 2, 3, or 4, wherein each mass tag has a molecular weight of from about 100Da to about 2,500Da
19. The method of claim 1 or 3 wherein the mass tag has the structure:
wherein X is H, F, OMe, or (OMe)2.
wherein X is H, F, OMe, or (OMe)2.
20. The method of claim 2 or 4, wherein one of the mass tags has the structure:
wherein X is H, F, OMe, or (OMe)2.
wherein X is H, F, OMe, or (OMe)2.
21. A composition of matter comprising:
(a) a solid substrate;
(b) a first antibody bound to the solid substrate, wherein the first antibody recognizes an agent;
(c) the agent recognized by the first antibody, wherein the agent is bound to the first antibody; and (d) a second antibody which recognizes the agent bound concurrently to the first antibody, wherein the second antibody is bound to the agent, and wherein the second antibody has a mass tag cleavably affixed thereto.
(a) a solid substrate;
(b) a first antibody bound to the solid substrate, wherein the first antibody recognizes an agent;
(c) the agent recognized by the first antibody, wherein the agent is bound to the first antibody; and (d) a second antibody which recognizes the agent bound concurrently to the first antibody, wherein the second antibody is bound to the agent, and wherein the second antibody has a mass tag cleavably affixed thereto.
22. A kit for detecting the presence of an agent in a sample comprising:
(a) a solid substrate;
(b) a first antibody for affixing to the solid substrate, which first antibody recognizes the agent;
(c) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (d) instructions for using the kit to detect the presence of the agent in the sample.
(a) a solid substrate;
(b) a first antibody for affixing to the solid substrate, which first antibody recognizes the agent;
(c) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (d) instructions for using the kit to detect the presence of the agent in the sample.
23. A kit for detecting the presence of an agent in a sample comprising:
(a) a solid substrate having affixed thereto a first antibody which recognizes the agent;
(b) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (c) instructions for using the kit to detect the presence of the agent in the sample.
(a) a solid substrate having affixed thereto a first antibody which recognizes the agent;
(b) a second antibody having a mass tag cleavably affixed thereto, which second antibody recognizes the agent concurrently with the first antibody; and (c) instructions for using the kit to detect the presence of the agent in the sample.
24. A kit for detecting the presence of an agent in a sample comprising:, (a) a solid substrate which binds the agent;
(b) an antibody having a mass tag cleavably affixed thereto, which antibody recognizes the agent;
and (c) instructions for using the kit to detect the presence of the agent in the sample.
(b) an antibody having a mass tag cleavably affixed thereto, which antibody recognizes the agent;
and (c) instructions for using the kit to detect the presence of the agent in the sample.
25. A kit for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) a solid substrate;
(b) a plurality of first antibodies for affixing to the solid substrate wherein for each agent whose presence is being detected in the sample there is at least one first antibody which binds to the agent;
(c) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any, other agent; and (d) instructions for using the kit to detect the presence in the sample of one or more agents.
(a) a solid substrate;
(b) a plurality of first antibodies for affixing to the solid substrate wherein for each agent whose presence is being detected in the sample there is at least one first antibody which binds to the agent;
(c) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any, other agent; and (d) instructions for using the kit to detect the presence in the sample of one or more agents.
26. A kit for detecting the presence in a sample of one or more of a plurality of agents comprising:
(a) a solid substrate having a plurality of first antibodies affixed thereto wherein for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent;
(b) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
(a) a solid substrate having a plurality of first antibodies affixed thereto wherein for each agent whose presence in the sample is being detected, there is at least one first antibody which binds to the agent;
(b) a plurality of second antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is to be detected, there is at least one second antibody which binds to the agent concurrently with its respective first antibody, and the mass tag or mass tags bound to the second antibody or antibodies, respectively, which bind to that agent have a different mass than that of the mass tag bound to any second antibody which binds to any other agent; and (c) instructions for using the kit to detect the presence in the sample of one or more agents.
27. A kit for detecting the presence of one or more of a plurality of agents in a sample comprising:
(a) a solid substrate which binds each of the agents whose presence is to be detected;
(b) a plurality of antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent; and (c) instructions for using the kit to detect the presence in the sample of one or more'agents.
(a) a solid substrate which binds each of the agents whose presence is to be detected;
(b) a plurality of antibodies each having a mass tag cleavably affixed thereto, wherein for each agent whose presence in the sample is being detected, there is at least one antibody which binds to the agent; and (c) instructions for using the kit to detect the presence in the sample of one or more'agents.
28. The kit of any of claims 21-27, wherein the sample is an aqueous cell suspension, a cell lysate, blood, plasma, lymph, cerebro-spinal fluid, tears, saliva, urine, synovial fluid, or a fluid derived from any of the above.
29. The kit of any of claim 21-27, wherein the sample is of mammalian origin.
30. The kit of claim 29, wherein the sample is of human origin.
31. The kit of any of claims 21-27, wherein the sample is of avian origin.
32. The kit of claim 21-27, wherein each antibody is a monoclonal antibody.
33. The kit of claim 32, wherein the monoclonal antibody is a chimeric monoclonal antibody.
34. The kit of any of claims 21-27, wherein the cleavable mass tag can be cleaved chemically, by ultraviolet light, by heat, or by laser.
35. The kit of any of claims 21-27, wherein the solid substrate is glass, quartz, silicon, plastic, or gold.
36. The kit of any of claims 21-27, wherein the solid substrate is a bead, a chip, or a well.
37. The kit of any of claims 21-27, wherein each affixed antibody is affixed to the solid substrate via a streptavidin-biotin link or via 1,3-dipolar cycloaddition.
38. The kit of any of claims 21-27, wherein the kit is for detecting the presence of bacterial antigen or a viral antigen.
39. The kit of any of claims 21-27, wherein each mass tag has a molecular weight of from about 100Da to about 2,500Da
40. The kit of any of claims 21-27, wherein the mass tag, or one of the mass tags, as applicable, has the structure:
wherein X is H, F, OMe, or (OMe)2.
wherein X is H, F, OMe, or (OMe)2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73876505P | 2005-11-21 | 2005-11-21 | |
| US60/738,765 | 2005-11-21 | ||
| PCT/US2006/045180 WO2007062105A2 (en) | 2005-11-21 | 2006-11-20 | Multiplex digital immuno-sensing using a library of photocleavable mass tags |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2630544A1 true CA2630544A1 (en) | 2007-05-31 |
Family
ID=38067892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002630544A Abandoned CA2630544A1 (en) | 2005-11-21 | 2006-11-20 | Multiplex digital immuno-sensing using a library of photocleavable mass tags |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090088332A1 (en) |
| EP (1) | EP1957983A4 (en) |
| AU (1) | AU2006318462A1 (en) |
| CA (1) | CA2630544A1 (en) |
| WO (1) | WO2007062105A2 (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790736A3 (en) | 2000-10-06 | 2007-08-15 | The Trustees Of Columbia University In The City Of New York | Massive parallel method for decoding DNA and RNA |
| US9708358B2 (en) | 2000-10-06 | 2017-07-18 | The Trustees Of Columbia University In The City Of New York | Massive parallel method for decoding DNA and RNA |
| WO2005084367A2 (en) | 2004-03-03 | 2005-09-15 | The Trustees Of Columbia University In The City Of New York | Photocleavable fluorescent nucleotides for dna sequencing on chip constructed by site-specific coupling chemistry |
| US9169510B2 (en) | 2005-06-21 | 2015-10-27 | The Trustees Of Columbia University In The City Of New York | Pyrosequencing methods and related compositions |
| GB2446084B (en) | 2005-10-31 | 2011-03-02 | Univ Columbia | Synthesis of four color 3-o-allyl modified photocleavable fluorescent nucleotides and related methods |
| GB2446083B (en) | 2005-10-31 | 2011-03-02 | Univ Columbia | Chemically cleavable 3'-0-allyl-dntp-allyl-fluorophore fluorescent nucleotide analogues and related methods |
| WO2007146158A1 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Columbia University In The City Of New York | Dna sequencing by nanopore using modified nucleotides |
| GB2457402B (en) | 2006-12-01 | 2011-10-19 | Univ Columbia | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators |
| US8278057B2 (en) * | 2007-09-14 | 2012-10-02 | Nestec S.A. | Addressable antibody arrays and methods of use |
| EP2725107B1 (en) | 2007-10-19 | 2018-08-29 | The Trustees of Columbia University in the City of New York | DNA sequencing with non-fluorescent nucleotide reversible terminators and cleavable label modified ddNTPs and nucleic acid comprising inosine with reversible terminators |
| WO2009051807A1 (en) | 2007-10-19 | 2009-04-23 | The Trustees Of Columbia University In The City Of New York | Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequencing by synthesis |
| US20090286286A1 (en) * | 2007-11-06 | 2009-11-19 | Ambergen , Inc. | Methods for controlling amplification |
| US8906700B2 (en) * | 2007-11-06 | 2014-12-09 | Ambergen, Inc. | Methods and compositions for phototransfer |
| US8673267B2 (en) | 2009-03-02 | 2014-03-18 | Massachusetts Institute Of Technology | Methods and products for in vivo enzyme profiling |
| US20120196297A1 (en) * | 2009-07-14 | 2012-08-02 | Yost Richard A | Mass tags for mass spectrometric analysis of immunoglobulins |
| CA2774422C (en) | 2009-10-12 | 2017-08-29 | Ventana Medical Systems, Inc. | Multi-modality contrast and brightfield context rendering for enhanced pathology determination and multi-analyte detection in tissue |
| US9678055B2 (en) | 2010-02-08 | 2017-06-13 | Genia Technologies, Inc. | Methods for forming a nanopore in a lipid bilayer |
| US8324914B2 (en) | 2010-02-08 | 2012-12-04 | Genia Technologies, Inc. | Systems and methods for characterizing a molecule |
| US9605307B2 (en) | 2010-02-08 | 2017-03-28 | Genia Technologies, Inc. | Systems and methods for forming a nanopore in a lipid bilayer |
| US9523680B2 (en) | 2010-06-30 | 2016-12-20 | Ambergen, Inc. | Global Proteomic screening of random bead arrays using mass spectrometry imaging |
| US9291597B2 (en) | 2010-07-02 | 2016-03-22 | Ventana Medical Systems, Inc. | Detecting targets using mass tags and mass spectrometry |
| GB2500360B (en) | 2010-12-22 | 2019-10-23 | Genia Tech Inc | Nanopore-based single DNA molecule characterization, identification and isolation using speed bumps |
| US9581563B2 (en) | 2011-01-24 | 2017-02-28 | Genia Technologies, Inc. | System for communicating information from an array of sensors |
| US9110478B2 (en) | 2011-01-27 | 2015-08-18 | Genia Technologies, Inc. | Temperature regulation of measurement arrays |
| CA2830235C (en) | 2011-03-15 | 2023-10-24 | Massachusetts Institute Of Technology | Multiplexed detection with isotope-coded reporters |
| US8986629B2 (en) | 2012-02-27 | 2015-03-24 | Genia Technologies, Inc. | Sensor circuit for controlling, detecting, and measuring a molecular complex |
| EP2861768A4 (en) | 2012-06-15 | 2016-03-02 | Genia Technologies Inc | Chip set-up and high-accuracy nucleic acid sequencing |
| US9605309B2 (en) | 2012-11-09 | 2017-03-28 | Genia Technologies, Inc. | Nucleic acid sequencing using tags |
| US9759711B2 (en) | 2013-02-05 | 2017-09-12 | Genia Technologies, Inc. | Nanopore arrays |
| EP2767832A1 (en) | 2013-02-18 | 2014-08-20 | Imabiotech | Photo or chemolabile conjugates for molecules detection |
| US10648026B2 (en) | 2013-03-15 | 2020-05-12 | The Trustees Of Columbia University In The City Of New York | Raman cluster tagged molecules for biological imaging |
| WO2014144898A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Method for detecting multiple predetermined compounds in a sample |
| EP3004374B1 (en) | 2013-06-07 | 2020-08-12 | Massachusetts Institute of Technology | Affinity-based detection of ligand-encoded synthetic biomarkers |
| US9551697B2 (en) | 2013-10-17 | 2017-01-24 | Genia Technologies, Inc. | Non-faradaic, capacitively coupled measurement in a nanopore cell array |
| EP3060918B1 (en) | 2013-10-23 | 2019-09-18 | Genia Technologies, Inc. | High speed molecular sensing with nanopores |
| US9322062B2 (en) | 2013-10-23 | 2016-04-26 | Genia Technologies, Inc. | Process for biosensor well formation |
| US10656157B2 (en) * | 2014-09-24 | 2020-05-19 | Purdue Research Foundation | Rare event detection using mass tags |
| US11448643B2 (en) | 2016-04-08 | 2022-09-20 | Massachusetts Institute Of Technology | Methods to specifically profile protease activity at lymph nodes |
| WO2017193070A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| KR101940622B1 (en) * | 2016-05-31 | 2019-01-21 | 다이아텍코리아 주식회사 | Assay for diagnosis of diseases using mass tag compound and the use thereof |
| AU2018248327A1 (en) | 2017-04-07 | 2019-10-17 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| GB2605470A (en) * | 2020-10-29 | 2022-10-05 | Ambergen Inc | Novel photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) * | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US5118605A (en) * | 1984-10-16 | 1992-06-02 | Chiron Corporation | Polynucleotide determination with selectable cleavage sites |
| US4824775A (en) * | 1985-01-03 | 1989-04-25 | Molecular Diagnostics, Inc. | Cells labeled with multiple Fluorophores bound to a nucleic acid carrier |
| US5174962A (en) * | 1988-06-20 | 1992-12-29 | Genomyx, Inc. | Apparatus for determining DNA sequences by mass spectrometry |
| US5302509A (en) * | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| NL9000436A (en) * | 1990-02-23 | 1991-09-16 | Meyn Maschf | DEVICE FOR PROVIDING A SIMULTANEOUS ROTATION MOVEMENT ON AN OBJECT MOVING UNDER A STRAIGHT TRACK. |
| US5197557A (en) * | 1991-12-10 | 1993-03-30 | Yanh Li Hsiang | Electronic weighing scale |
| GB9208733D0 (en) * | 1992-04-22 | 1992-06-10 | Medical Res Council | Dna sequencing method |
| GB9315847D0 (en) * | 1993-07-30 | 1993-09-15 | Isis Innovation | Tag reagent and assay method |
| CA2170264A1 (en) * | 1993-09-10 | 1995-03-16 | Michael W. Konrad | Optical detection of position of oligonucleotides on large dna molecules |
| WO1995014108A1 (en) * | 1993-11-17 | 1995-05-26 | Amersham International Plc | Primer extension mass spectroscopy nucleic acid sequencing method |
| US5654419A (en) * | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
| US6028190A (en) * | 1994-02-01 | 2000-02-22 | The Regents Of The University Of California | Probes labeled with energy transfer coupled dyes |
| US5869255A (en) * | 1994-02-01 | 1999-02-09 | The Regents Of The University Of California | Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis |
| US5552278A (en) * | 1994-04-04 | 1996-09-03 | Spectragen, Inc. | DNA sequencing by stepwise ligation and cleavage |
| US20020168642A1 (en) * | 1994-06-06 | 2002-11-14 | Andrzej Drukier | Sequencing duplex DNA by mass spectroscopy |
| US5872244A (en) * | 1994-09-02 | 1999-02-16 | Andrew C. Hiatt | 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds |
| US6214987B1 (en) * | 1994-09-02 | 2001-04-10 | Andrew C. Hiatt | Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides |
| US5763594A (en) * | 1994-09-02 | 1998-06-09 | Andrew C. Hiatt | 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds |
| US5808045A (en) * | 1994-09-02 | 1998-09-15 | Andrew C. Hiatt | Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides |
| US5728528A (en) * | 1995-09-20 | 1998-03-17 | The Regents Of The University Of California | Universal spacer/energy transfer dyes |
| US5945283A (en) * | 1995-12-18 | 1999-08-31 | Washington University | Methods and kits for nucleic acid analysis using fluorescence resonance energy transfer |
| US6613508B1 (en) * | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
| US6312893B1 (en) * | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| US6361940B1 (en) * | 1996-09-24 | 2002-03-26 | Qiagen Genomics, Inc. | Compositions and methods for enhancing hybridization and priming specificity |
| GB9620209D0 (en) * | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| US5853992A (en) * | 1996-10-04 | 1998-12-29 | The Regents Of The University Of California | Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels |
| US5885775A (en) * | 1996-10-04 | 1999-03-23 | Perseptive Biosystems, Inc. | Methods for determining sequences information in polynucleotides using mass spectrometry |
| DE69735445T2 (en) * | 1996-12-10 | 2006-08-10 | Sequenom, Inc., San Diego | NON-VOLATILE, NON-VOLATILE MOLECULES FOR MASS MARKING |
| US5876936A (en) * | 1997-01-15 | 1999-03-02 | Incyte Pharmaceuticals, Inc. | Nucleic acid sequencing with solid phase capturable terminators |
| US5804386A (en) * | 1997-01-15 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | Sets of labeled energy transfer fluorescent primers and their use in multi component analysis |
| US6046005A (en) * | 1997-01-15 | 2000-04-04 | Incyte Pharmaceuticals, Inc. | Nucleic acid sequencing with solid phase capturable terminators comprising a cleavable linking group |
| WO1998033939A1 (en) * | 1997-01-31 | 1998-08-06 | Hitachi, Ltd. | Method for determining nucleic acid base sequence and apparatus therefor |
| US6232456B1 (en) * | 1997-10-06 | 2001-05-15 | Abbott Laboratories | Serine protease reagents and methods useful for detecting and treating diseases of the prostate |
| US6218530B1 (en) * | 1998-06-02 | 2001-04-17 | Ambergen Inc. | Compounds and methods for detecting biomolecules |
| US6218118B1 (en) * | 1998-07-09 | 2001-04-17 | Agilent Technologies, Inc. | Method and mixture reagents for analyzing the nucleotide sequence of nucleic acids by mass spectrometry |
| US6787308B2 (en) * | 1998-07-30 | 2004-09-07 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
| US20030054360A1 (en) * | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
| DE60044490D1 (en) * | 1999-02-23 | 2010-07-15 | Caliper Life Sciences Inc | MANIPULATION OF MICROTEILS IN MICROFLUID SYSTEMS |
| US6316230B1 (en) * | 1999-08-13 | 2001-11-13 | Applera Corporation | Polymerase extension at 3′ terminus of PNA-DNA chimera |
| CA2385475A1 (en) * | 1999-08-16 | 2001-02-22 | Human Genome Sciences, Inc. | 18 human secreted proteins |
| US6664399B1 (en) * | 1999-09-02 | 2003-12-16 | E. I. Du Pont De Nemours & Company | Triazole linked carbohydrates |
| AU7537200A (en) * | 1999-09-29 | 2001-04-30 | Solexa Ltd. | Polynucleotide sequencing |
| WO2001057067A1 (en) * | 2000-02-04 | 2001-08-09 | Supratek Pharma Inc. | Ligand for vascular endothelial growth factor receptor |
| US20020106648A1 (en) * | 2000-05-05 | 2002-08-08 | Lizardi Paul M. | Highly multiplexed reporter carrier systems |
| CA2416631C (en) * | 2000-08-03 | 2011-11-22 | F. Hoffmann-La Roche Ag | Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses |
| AU8356201A (en) * | 2000-08-11 | 2002-02-25 | Agilix Corp | Ultra-sensitive detection systems |
| US6627748B1 (en) * | 2000-09-11 | 2003-09-30 | The Trustees Of Columbia University In The City Of New York | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses |
| US20060057565A1 (en) * | 2000-09-11 | 2006-03-16 | Jingyue Ju | Combinatorial fluorescence energy transfer tags and uses thereof |
| EP1790736A3 (en) * | 2000-10-06 | 2007-08-15 | The Trustees Of Columbia University In The City Of New York | Massive parallel method for decoding DNA and RNA |
| US20030027140A1 (en) * | 2001-03-30 | 2003-02-06 | Jingyue Ju | High-fidelity DNA sequencing using solid phase capturable dideoxynucleotides and mass spectrometry |
| US6573677B2 (en) * | 2001-06-18 | 2003-06-03 | Motorola, Inc. | Method of compensating for abrupt load changes in an anti-pinch window control system |
| US6613523B2 (en) * | 2001-06-29 | 2003-09-02 | Agilent Technologies, Inc. | Method of DNA sequencing using cleavable tags |
| AU2002354577B2 (en) * | 2001-07-13 | 2007-02-08 | Ambergen, Inc. | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof |
| US6902904B2 (en) * | 2001-08-27 | 2005-06-07 | Pharmanetics Incorporated | Coagulation assay reagents containing lanthanides |
| US7057026B2 (en) * | 2001-12-04 | 2006-06-06 | Solexa Limited | Labelled nucleotides |
| JP2003217397A (en) * | 2002-01-25 | 2003-07-31 | Matsushita Electric Ind Co Ltd | Rotary electronic part |
| US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
| US7074597B2 (en) * | 2002-07-12 | 2006-07-11 | The Trustees Of Columbia University In The City Of New York | Multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry |
| US20050032081A1 (en) * | 2002-12-13 | 2005-02-10 | Jingyue Ju | Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry |
| US20060252938A1 (en) * | 2003-04-28 | 2006-11-09 | Basf Aktiengesellschaft | Process for the separation of palladium catalyst from crude reaction mixtures of aryl acetic acids obtained by carbonylation |
| GB0321306D0 (en) * | 2003-09-11 | 2003-10-15 | Solexa Ltd | Modified polymerases for improved incorporation of nucleotide analogues |
| US7569392B2 (en) * | 2004-01-08 | 2009-08-04 | Vanderbilt University | Multiplex spatial profiling of gene expression |
| WO2005067648A2 (en) * | 2004-01-08 | 2005-07-28 | Vanderbilt University | Multiplex spatial profiling of gene expression |
| US7622026B2 (en) * | 2004-03-02 | 2009-11-24 | Panasonic Corporation | Biosensor |
| WO2005084367A2 (en) * | 2004-03-03 | 2005-09-15 | The Trustees Of Columbia University In The City Of New York | Photocleavable fluorescent nucleotides for dna sequencing on chip constructed by site-specific coupling chemistry |
| WO2006073436A2 (en) * | 2004-04-29 | 2006-07-13 | The Trustees Of Columbia University In The City Of New York | Mass tag pcr for multiplex diagnostics |
| US20060105461A1 (en) * | 2004-10-22 | 2006-05-18 | May Tom-Moy | Nanopore analysis system |
-
2006
- 2006-11-20 AU AU2006318462A patent/AU2006318462A1/en not_active Abandoned
- 2006-11-20 CA CA002630544A patent/CA2630544A1/en not_active Abandoned
- 2006-11-20 US US12/085,343 patent/US20090088332A1/en not_active Abandoned
- 2006-11-20 EP EP06838256A patent/EP1957983A4/en not_active Withdrawn
- 2006-11-20 WO PCT/US2006/045180 patent/WO2007062105A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20090088332A1 (en) | 2009-04-02 |
| EP1957983A4 (en) | 2010-03-24 |
| WO2007062105A3 (en) | 2009-04-30 |
| EP1957983A2 (en) | 2008-08-20 |
| WO2007062105A8 (en) | 2007-09-07 |
| WO2007062105A2 (en) | 2007-05-31 |
| AU2006318462A1 (en) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090088332A1 (en) | Multiplex Digital Immuno-Sensing Using a Library of Photocleavable Mass Tags | |
| US5770457A (en) | Rapid oneside single targeting (ROST) immunoassay method | |
| US20070148707A1 (en) | Systems and methods for detection of analytes in biological fluids | |
| JP5337101B2 (en) | Immune complex-specific antibodies for reducing blank values in array test formats when detecting antigen-specific antibodies of specific immunoglobulin class | |
| US5935780A (en) | Method for the qualitative or/and quantitative detection of an analyte | |
| JP5813111B2 (en) | Co-coupling to control reagent reactivity in immunoassays | |
| JP5414667B2 (en) | Method for detecting specific immunoglobulin class G antibody | |
| EP0201211A1 (en) | Method and compositions for visual solid phase immunoassays based on luminescent microspheric particles | |
| AU668937B2 (en) | Process for the immunochemical determination of an analyte | |
| JPH06174711A (en) | Indirect chromatographic antigen sandwich test for detecting specific antibody and device thereof | |
| Smith et al. | Determination of ANA specificity using the UltraPlex™ platform | |
| US7262019B2 (en) | System and methods for detection of Bacillus anthracis related analytes in biological fluids | |
| JP2002340897A (en) | Immuno-chromatograph method enabling simultaneous analysis of plural items and total content and strip for immuno-chromatograph | |
| US5437981A (en) | Method for the immunological determination of ligands | |
| US20080233594A1 (en) | Method For Detecting An At Least Bivalent Analyte Using Two Affinity Reactants | |
| JP4554356B2 (en) | Sandwich assays and kits | |
| JPH03170058A (en) | Reagent complex for immunoassay | |
| WO1987002779A1 (en) | Idiotypic-antigenic conjunction binding assay | |
| JPH10319017A (en) | Measuring method for substance utilizing fluorescent energy transfer and reagent therefor | |
| WO1999041611A1 (en) | Assaying of antibodies directed against one or more antigens of helicobacter pylori in biological liquids by a heterogeneous immunologic method of the reverse type | |
| JP5137880B2 (en) | Method for producing dry particles with immobilized binding substance | |
| JP4302798B2 (en) | Method for preparing ligand binding surface | |
| EP0985931A2 (en) | Recombinant antigen immunoassay for the diagnosis of syphilis | |
| JPH08114595A (en) | Specific bonding measuring method | |
| CN114181909A (en) | Hybridoma cell strain, monoclonal antibody and kit thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20121120 |